

Special Issue

Non-Contrast Breast Cancer MRI Screening: Diffusion-Weighted Imaging, DWIBS, and Clinical Implementation

Message from the Guest Editor

Breast cancer screening is key to reducing mortality. Mammography, the current standard, is limited by pain, embarrassment, radiation, and reduced sensitivity in dense breasts. Contrast-enhanced MRI offers high sensitivity but is constrained by contrast use, cost, long exam time, and impracticality for repeat screening. This Special Issue aims to explore the emerging role of non-contrast breast MRI, particularly diffusion-weighted imaging and diffusion-weighted whole-body imaging with background body signal suppression (DWIBS), in breast cancer screening. In this Special Issue, original research articles, reviews, technical notes, perspectives are welcome. Research areas may include, but are not limited to, non-contrast breast MRI, diffusion-weighted imaging, DWIBS, screening performance, cancer detection rate, positive predictive value, dense breasts, image-quality control, remote interpretation, artificial intelligence, and clinical pathways after positive screening findings. I look forward to receiving your contributions.

Guest Editor

Dr. Taro Takahara

1. Takahara Clinic Innovative Scan, Tokyo, Japan
2. DWIBS Search Inc., Tokyo, Japan
3. Faculty of Medicine, Institute of Science Tokyo, Tokyo, Japan

Deadline for manuscript submissions

31 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/281611

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)